Bellerophon Therapeutics (NASDAQ:BLPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. “
Several other analysts have also recently weighed in on BLPH. HC Wainwright restated a “buy” rating on shares of Bellerophon Therapeutics in a report on Friday, May 11th. ValuEngine upgraded Bellerophon Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, June 8th.
Shares of NASDAQ:BLPH traded up $0.06 during midday trading on Wednesday, hitting $2.65. 302,600 shares of the stock were exchanged, compared to its average volume of 251,291. The stock has a market cap of $155.55 million, a P/E ratio of -2.94 and a beta of -0.43. Bellerophon Therapeutics has a 12 month low of $1.00 and a 12 month high of $3.30.
Hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC bought a new stake in Bellerophon Therapeutics in the fourth quarter valued at approximately $146,000. Renaissance Technologies LLC boosted its holdings in Bellerophon Therapeutics by 25.3% in the fourth quarter. Renaissance Technologies LLC now owns 927,200 shares of the biotechnology company’s stock valued at $2,392,000 after acquiring an additional 187,200 shares during the last quarter. DRW Securities LLC bought a new stake in Bellerophon Therapeutics in the first quarter valued at approximately $146,000. Finally, Bank of New York Mellon Corp bought a new stake in Bellerophon Therapeutics in the fourth quarter valued at approximately $458,000. Institutional investors and hedge funds own 58.10% of the company’s stock.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.